Elidah
Elidah is a Connecticut-based medical device company that sells Elitone, an FDA-cleared external neuromuscular stimulation device for women with urinary incontinence. It markets directly to consumers via e-commerce, CVS retail, and Medicare Part B telehealth pathways, and has expanded into a men's post-prostatectomy product line.
- Company typePrivate
- Founded2015
- HeadquartersMonroe, United States
- Headcount11–50
- GTM typeB2C
- OfferingHardware or Manufacturing
What Elidah does
Elidah Inc. is a privately held medical device company founded in 2014/2015 by biomedical engineer Gloria Kolb, headquartered in Monroe, Connecticut. The company develops and sells the Elitone platform of FDA-cleared, external (non-vaginal, non-invasive) neuromuscular stimulation devices for the treatment of urinary incontinence. Its core technology centers on a proprietary Pre-Modulated Waveform (PMW) delivered through a patented perineal GelPad with four conductive regions, enabling electrical stimulation to reach pelvic floor muscles through the skin without internal probes. The product portfolio comprises Elitone for stress and mixed urinary incontinence, Elitone URGE for overactive bladder, and Elitone for Men for post-prostatectomy incontinence, with companion GelPad consumables and accessories.
Elidah operates a primarily direct-to-consumer go-to-market model through its e-commerce site (elitone.com), supplemented by retail distribution via CVS Pharmacy, a Medicare Part B billing pathway enabled through a telehealth partnership with MD Integrations, clinician office sales, and a 2025 distribution partnership with women's-health platform FEMSelect. The Starter Kit is priced at $429 and the Bundle at $539, with recurring revenue from GelPad refill packs at $33 for a pack of five; Medicare-eligible patients can access treatment at a co-pay as low as $11-12/month. The company has treated over 40,000 women cumulatively across roughly a decade of operation, has accumulated 1,000+ verified customer reviews with an average 4.5-star rating, and references 100,000+ users of its online assessment quiz. Clinical evidence supporting the platform includes randomized controlled trials showing 95% of women reporting fewer leaks and a 71% average reduction in leaks after six weeks of treatment. The company has raised approximately $6.4M+ across disclosed rounds, completed a Blu Venture Investors-led Series A in January 2024, and brought in additional capital in April 2026.
Elidah firmographics
Firmographics- Name
- Elidah
- Legal name
- Elidah Inc.
- Website
- https://elitone.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Elidah is a Connecticut-based medical device company that sells Elitone, an FDA-cleared external neuromuscular stimulation device for women with urinary incontinence. It markets directly to consumers via e-commerce, CVS retail, and Medicare Part B telehealth pathways, and has expanded into a men's post-prostatectomy product line.
- Ownership category
- akta.pro rank
Elidah industry classification
Industry- Product category
- Pelvic Floor Therapy Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Continence Care Products (Adult Incontinence Pads/Briefs, Underpads, External Collectors) (HLAHALAH)
- akta.pro secondary industry
- Posture, Musculoskeletal & Pain-Relief Devices (Posture Trainers, TENS/EMS, Massage Devices) (CRACAQAK)
Keywords
Where Elidah is headquartered
LocationHeadquarters
- HQ city
- Monroe
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Elidah business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
Revenue model
- Device Sales: One-time purchase of Elitone device (Starter Kit or Bundle) with GelPad packs included. Device is a reusable controller with disposable GelPads for ongoing treatment.
- GelPad Consumables: Ongoing consumable sales of GelPads (reusable 3+ times) for maintenance mode treatment. GelPad packs of 5 available for $33.
- Medicare Part B Billing: Direct billing to Medicare Part B for eligible patients with prescription. Patient co-pay typically around $150, potentially as low as $12/month through payment plans.
- Distribution Partnership Revenue: Revenue from FEMSelect distribution partnership expanding Elitone availability through their women's health platform.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | Starter Kit - Initial treatment package |
| One time/ perpetual license | Pay-as-you-go | Bundle - Extended treatment package |
| Subscription | Monthly | Medicare-covered option |
| Unit Pricing | Pay-as-you-go | GelPad Refill Packs |
| Unit Pricing | Monthly | Direct-to-consumer monthly financing |
Go-to-market motion1 record
Distribution channels5 records
Marketing channels7 records
Elidah product offering
Product offeringCore offering
Elidah develops, manufactures, and sells FDA-cleared external neuromuscular stimulation medical devices for treating urinary incontinence. Its flagship products—Elitone (stress incontinence), Elitone URGE (overactive bladder), and Elitone for Men (post-prostate surgery)—deliver proprietary Pre-Modulated Waveform stimulation through a patented perineal GelPad to strengthen pelvic floor muscles without invasive probes. Devices are sold direct-to-consumer via e-commerce and CVS, with Medicare Part B reimbursement available through a partnered telehealth provider.
Product overview
Elidah offers a portfolio of FDA-cleared external neuromuscular stimulation medical devices for treating urinary incontinence. The core products include Elitone (for stress incontinence), Elitone URGE (for urge/Overactive Bladder), and Elitone for Men (for post-prostate surgery recovery). All devices use a patented external GelPad technology that delivers stimulation through the skin to pelvic floor muscles. The portfolio is complemented by replacement GelPad consumables and accessories like cables and compression socks. Products are available over-the-counter or via Medicare prescription, with treatment typically involving 20 minutes daily for 6 weeks.
Differentiator
Problem solved
Functional benefit
Brands
- Elitone: FDA-cleared external pelvic floor therapy device for treatment of stress urinary incontinence in women. Delivers neuromuscular stimulation through the skin.
- Elitone URGE
- Elitone for Men
- GelPads
Products and services
- Elitone FDA-cleared external neuromuscular stimulation device for treating stress urinary incontinence in women. Worn externally on the perineal area for 20-minute daily sessions, it contracts pelvic floor muscles to reduce leaks associated with coughing, sneezing, or exercise. Sold OTC and via Medicare Part B.
- Elitone URGE FDA-cleared external neuromuscular stimulation device for treating urge urinary incontinence (Overactive Bladder) in women. Uses calming signals (6 sec calming signal + 6 sec rest cycle) to relax overactive bladder muscles, reducing sudden urges to urinate. Sold direct-to-consumer; not available outside the U.S.
- Elitone for Men FDA-cleared external neuromuscular stimulation device for men recovering bladder control after prostate surgery. Delivers neuromuscular stimulation to strengthen pelvic muscles, available over the counter and covered by Medicare.
- GelPads (Women) Replacement consumable hydrogel pads for Elitone and Elitone URGE devices. Patented low-tack hydrogel with four conductive regions, reusable at least 3 times, designed for comfortable skin contact over hair.
- GelPads (Men) Replacement consumable hydrogel pads specifically designed for the Elitone for Men device.
- Compression Socks Compression socks designed to reduce stress and support leg circulation for women dealing with incontinence-related lifestyle impacts.
- Cables Replacement cables for Elitone devices, included with both Elitone and Elitone URGE products.
Quantifiable outcome
- 95% of women reported fewer leaks after 6 weeks of treatment
- +4 more outcomes
Companies that use Elidah
Customer profileNamed customers1 record
Segments5 records
Ideal customer profiles4 records
Elidah technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
Feature4 records
Elidah partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- FEMSelectcoreFEMSelect, a privately held women-led company focused on pelvic health, announced strategic partnership to distribute Elitone FDA-cleared medical devices. Partnership expands FEMSelect's portfolio beyond its EnPlace product for pelvic organ prolapse into the incontinence market. Follows FEMSelect's oversubscribed Series B financing and supports their growth strategy to build a comprehensive women's health solutions platform.
- MD IntegrationscoreLicensed telehealth provider partnership enabling prescription processing for Medicare and insurance coverage. MD Integrations provides online health questionnaire review by board-certified physicians. Consultation fee of $22 covers physician review. Most patients do not require scheduled video visits.
- CVS PharmacycoreRetail pharmacy partner for over-the-counter distribution of Elitone products. Products available in CVS Pharmacy locations alongside other health and wellness products.
- PayPalminorPayPal Pay Later financing option offering interest-free payments within 6 months for Elitone purchases. Enables affordable payment options for customers.
- AffirmminorMonthly payment plan provider offering multiple plan options for Elitone purchases. Interest may apply depending on plan selected. Quick approval process that does not affect credit score.
Scale indicators9 records
Recent moves6 records
Expansion highlights6 records
Elidah competitors and assessment
Company assessmentDirect peers
- Atlantic Therapeutics: Maker of the INNOVO external pelvic floor stimulation shorts for stress urinary incontinence. Most directly comparable competitor to Elitone in the external NMES category for at-home incontinence treatment.
- Renovia: Developer of the Leva pelvic floor muscle training device for female stress urinary incontinence. Competes with Elitone in FDA-cleared, non-surgical, at-home pelvic floor therapy targeting the same female consumer.
- InControl Medical: Markets InTone and InToneMV devices that use neuromuscular stimulation to treat stress, urge, and mixed incontinence. Closely comparable FDA-cleared medical device competitor in the pelvic floor stimulation category.
- Elvie (Chiaro Technology): Consumer femtech brand offering the Elvie Trainer and Elvie Pump, with overlap into connected pelvic floor training. Comparable in DTC go-to-market, female consumer focus, and brand-led positioning, though Elvie is broader across women's health.
- Perifit: Connected pelvic floor trainer (Perifit Care) for at-home Kegel biofeedback and urinary incontinence. Competes with Elitone in DTC, app-connected pelvic floor therapy for the same female consumer segment.
- TensCare: Manufacturer of TENS/EMS devices including pelvic floor stimulators (e.g., iTouch Sure, Elise) sold across UK and Europe. Overlaps with Elitone in TENS/EMS technology platform and consumer-direct distribution of stimulation products.
Broad incumbents
- Axonics (Boston Scientific): Acquired by Boston Scientific, Axonics makes sacral neuromodulation (SNM) systems for urge incontinence and overactive bladder. A larger, well-capitalized competitor operating in the same therapy area through an implanted-device approach.
- Medtronic: Through InterStim, Medtronic is the established leader in sacral neuromodulation for urinary incontinence. Represents the dominant incumbent against which Elitone competes for share of voice and clinician adoption.
- Laborie Medical Technologies: Global urogynecology and pelvic health diagnostics/therapeutics company with a broad incontinence portfolio. Comparable as a larger incumbent operating across pelvic floor assessment and treatment, including stimulation-adjacent solutions.
Emerging players
- FEMSelect: Women-led pelvic health company behind the EnPlace pelvic organ prolapse device; strategic distribution partner for Elitone. Comparable as a focused women's pelvic health device company and overlapping commercial channel, though its core product targets prolapse rather than incontinence.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Elidah social profiles
Digital presenceElidah compliance and trust
Trust signalCompliance2 records
Elidah financial estimates
Financial estimateRevenue estimate
Valuation estimate
Elidah leadership team
Management profileNumber of profiles
Profiles2 records
Elidah funding detail
Funding detailFunding overview
Funding rounds6 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Elidah M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Elidah
What does Elidah do?
Elidah develops, manufactures, and sells FDA-cleared external neuromuscular stimulation medical devices for treating urinary incontinence. Its flagship products—Elitone (stress incontinence), Elitone URGE (overactive bladder), and Elitone for Men (post-prostate surgery)—deliver proprietary Pre-Modulated Waveform stimulation through a patented perineal GelPad to strengthen pelvic floor muscles without invasive probes. Devices are sold direct-to-consumer via e-commerce and CVS, with Medicare Part B reimbursement available through a partnered telehealth provider.
Is Elidah a public or private company?
Elidah is a private company. It is classified as venture growth investor backed and is currently operating.
When was Elidah founded?
Elidah was founded in 2015. It employs 11 to 50 people.
Where is Elidah based?
Elidah is headquartered in Monroe, United States, in the North America region.
How does Elidah make money?
Four revenue lines are on record. Device Sales are the primary driver. The others are gelPad Consumables, medicare Part B Billing and distribution Partnership Revenue.
Who are Elidah's main competitors?
Direct peers on record are Atlantic Therapeutics, Renovia, InControl Medical, Elvie (Chiaro Technology), Perifit and TensCare. Broad incumbents are Axonics (Boston Scientific), Medtronic and Laborie Medical Technologies. FEMSelect is listed as an emerging player.
Does Elidah have an API?
No public API is recorded for Elidah.
What industry is Elidah in?
Elidah's product category is Pelvic Floor Therapy Medical Devices. Its primary akta.pro industry code is HLAHALAH, Continence Care Products (Adult Incontinence Pads/Briefs, Underpads, External Collectors), with a secondary code of CRACAQAK, Posture, Musculoskeletal & Pain-Relief Devices (Posture Trainers, TENS/EMS, Massage Devices). Its NAICS code is 334510 and its SIC code is 3845.